MedWatch

Novo Nordisk's first phase III data for weekly insulin to be released in few months

The first data from Novo Nordisk’s phase III program, which goes under the name Onwards, with once-weekly insulin Icodec will arrive within a few months, says Novo exec Martin Holst Lange at the company’s capital markets day.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk is expecting to conclude its phase III program, dubbed Onwards, with its once-weekly insulin Icodec in 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs